The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Metabolomic profiling to develop blood biomarkers for Parkinson's disease
Open accessAbstract
The development of biomarkers for the diagnosis and monitoring disease progression in Parkinson's disease (PD) is of great importance since diagnosis based on clinical parameters has a considerable error rate. In this study, we utilized metabolomic profiling using high performance liquid chromatography coupled with electrochemical coulometric array detection (LCECA) to look for biomarkers in plasma useful for the diagnosis of PD. We examined 25 controls and 66 PD patients. We also measured 8-hydroxy-2-deoxyguanosine (8-OHdG) levels as a marker of oxidative damage to DNA. We initially examined the profiles of unmedicated PD subjects compared to controls to rule out confounding effects of symptomatic medications. We found a complete separation of the two groups. We then determined the variables, which played the greatest role in separating the two groups and applied them to PD subjects taking dopaminergic medications. Using these parameters, we achieved a complete separation of the PD patients from controls. 8-OHdG levels were significantly increased in PD patients, but overlapped controls. Two other markers of oxidative damage were measured in our LCECA profiles. Uric acid was significantly reduced while glutathione was significantly increased in PD patients. These findings show that metabolomic profiling with LCECA coulometric array has great promise for developing biomarkers for both the diagnosis, as well as monitoring disease progression in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 2×
“Strong evidence relates mutations in these genes to protein aggregation, mitochondrial dysfunction and oxidative damage (Lin and Beal, 2006).”
BackgroundSelf-citationMetabonomics: a platform for studying drug toxicity and gene function
Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd728 · Cited by 1,914
Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1142 · Cited by 1,313
Metabolomics by numbers: acquiring and understanding global metabolite data
Goodacre, R., Vaidyanathan, S., Dunn, W. B., Harrigan, G. G., & Kell, D. B. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.03.007 · Cited by 1,249
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
Abnormalities of the electron transport chain in idiopathic parkinson's disease
Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,063
Brindle, J. T., Antti, H., Holmes, E., Tranter, G., Nicholson, J. K., Bethell, H. W. L., Clarke, S., Schofield, P. M., McKilligin, E., Mosedale, D. E., et al. (2002) · Nature Medicine · doi:10.1038/nm1202-802 · Cited by 1,029
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 1×
“These include an NINDS-sponsored clinical trials of both coenzyme Q and creatine, which are thought to have beneficial effects on energy metabolism and oxidative stress (Shults et al., 2002; NINDS NET-PD Investigators, 2006).”
MethodExpression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
The Human Serum Metabolome (HUSERMET) Consortium, Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., Brown, M., Knowles, J. D., Halsall, A., et al. (2011) · Nature Protocols · doi:10.1038/nprot.2011.335 · Cited by 3,294
Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R., & Griffin, J. L. (2011) · Chem. Soc. Rev. · doi:10.1039/b906712b · Cited by 860
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
Henchcliffe, C., & Beal, M. F. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0924 · Cited by 783
Self-citationChemometrics in metabolomics—A review in human disease diagnosis
Madsen, R., Lundstedt, T., & Trygg, J. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.11.042 · Cited by 557
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Han, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429
Targeted Metabolomics for Biomarker Discovery
Griffiths, W. J., Koal, T., Wang, Y., Kohl, M., Enot, D. P., & Deigner, H. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200905579 · Cited by 415
Smolinska, A., Blanchet, L., Buydens, L. M. C., & Wijmenga, S. S. (2012) · Analytica Chimica Acta · doi:10.1016/j.aca.2012.05.049 · Cited by 397
Circulating miRNA Biomarkers for Alzheimer's Disease
Kumar, P., Dezso, Z., MacKenzie, C., Oestreicher, J., Agoulnik, S., Byrne, M., Bernier, F., Yanagimachi, M., Aoshima, K., & Oda, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069807 · Cited by 381
Biomarkers of Parkinson’s disease: Present and future
Miller, D. B., & O’Callaghan, J. P. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.030 · Cited by 358
The dynamic range of the human metabolome revealed by challenges
Krug, S., Kastenmüller, G., Stückler, F., Rist, M. J., Skurk, T., Sailer, M., Raffler, J., Römisch‐Margl, W., Adamski, J., Prehn, C., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-198093 · Cited by 327
Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285
Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
Kaddurah-Daouk, R., & Krishnan, K. R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.174 · Cited by 293
Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases
Gan, L., & Johnson, J. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.011 · Cited by 288
Metabolomics tools for identifying biomarkers for neuropsychiatric diseases
Quinones, M. P., & Kaddurah-Daouk, R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.019 · Cited by 284
Identification of novel biomarkers for Parkinson's disease by metabolomic technologies
Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P., & Hattori, N. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309676 · Cited by 282
Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Monteiro, M. S., Carvalho, M., Bastos, M. L., & Guedes de Pinho, P. (2013) · Current Medicinal Chemistry · doi:10.2174/092986713804806621 · Cited by 279
Metabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases
Jové, M., Portero-Otín, M., Naudí, A., Ferrer, I., & Pamplona, R. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000091 · Cited by 195
Kim, S., Hwang, J., Xuan, J., Jung, Y. H., Cha, H.-S., & Kim, K. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097501 · Cited by 169
Biomarkers intersect with the exposome
Rappaport, S. M. (2012) · Biomarkers · doi:10.3109/1354750x.2012.691553 · Cited by 114
“Parkinson’s disease Neurologic 88 17 3 (Bogdanov et al. 2008)”
Metabolomic analysis of male combat veterans with post traumatic stress disorder
Mellon, S. H., Bersani, F. S., Lindqvist, D., Hammamieh, R., Donohue, D., Dean, K., Jett, M., Yehuda, R., Flory, J., Reus, V. I., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0213839 · Cited by 85
Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile
Kaddurah-Daouk, R., Yuan, P., Boyle, S. H., Matson, W., Wang, Z., Zeng, Z. B., Zhu, H., Dougherty, G. G., Yao, J. K., Chen, G., et al. (2012) · Scientific Reports · doi:10.1038/srep00667 · Cited by 76
Self-citationGonzalez-Riano, C., Saiz, J., Barbas, C., Bergareche, A., Huerta, J. M., Ardanaz, E., Konjevod, M., Mondragon, E., Erro, M. E., Chirlaque, M. D., et al. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-021-00216-4 · Cited by 49
Kumar, B. S., Chung, B. C., Kwon, O., & Jung, B. H. (2012) · Journal of Applied Toxicology · doi:10.1002/jat.1746 · Cited by 52
Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease
Yakhine-Diop, S. M. S., Morales-García, J. A., Niso-Santano, M., González-Polo, R. A., Uribe-Carretero, E., Martinez-Chacon, G., Durand, S., Maiuri, M. C., Aiastui, A., Zulaica, M., et al. (2020) · Aging · doi:10.18632/aging.103992 · Cited by 50
Fu, Y., Zhen, J., & Lu, Z. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3643 · Cited by 39
Metadata
- Authors
- Bogdanov, M., Matson, W. R., Wang, L., Matson, T., Saunders-Pullman, R., Bressman, S. S., & Beal, M. F.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-01
- Volume
- 131
- Issue
- 2
- Pages
- 389-396
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2117524242
- Cited by
- 401
- References
- 43
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.